Market revenue in 2022 | USD 197.6 million |
Market revenue in 2030 | USD 356.8 million |
Growth rate | 7.7% (CAGR from 2023 to 2030) |
Largest segment | Ferric carboxymaltose |
Fastest growing segment | Other Product |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product |
Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 56.73% in 2022. Horizon Databook has segmented the Germany intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose, other product covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is the largest contributor to the European market for IV iron drugs in 2022 and is anticipated to maintain its dominance over the forecast period. This can be attributed to high healthcare expenditure, easy availability of iron drugs, high prevalence of cancer, and increasing government support. Inflammatory bowel diseases affect between 320,000 and 470,000 patients in Germany.
Based on socio-economic and medical data, it has been observed that about 20% of German patients suffering from IBD may not be treated according to the clinical guidelines provided by the European Crohn’s and Colitis Organization (ECCO) or German Society of Gastroenterology (DGVS).
The rising incidence of anemia is another factor facilitating growth in the nation. Price regulation in Germany may cause an impact across the European pharma markets as many payers and regulators see Germany as a price reference market.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into Germany intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account